Results 41 to 50 of about 5,338,748 (296)

Histone variant H2A.J is an epigenetic regulator of metastasis in lung adenocarcinoma

open access: yesCell Death and Disease
Metastasis is a major contributor to poor patient survival in lung adenocarcinoma (LUAD); however, the underlying mechanisms remain incompletely understood.
Dong-Gun Kim   +4 more
doaj   +1 more source

What role does pyroptosis play in cancer?

open access: yesMolecular Metabolism, 2022
Background: Pyroptosis has been attracting much attention recently. We have briefly compared its differences and similarities with other programmed deaths and the process of its study. With further exploration of the caspase family, including caspase-1/3/
Chen Huang, Jian Li, Chenliang Zhang
doaj   +1 more source

Targeted Therapies for Melanoma [PDF]

open access: yesCancers, 2020
The incidence of cutaneous malignant melanoma (CMM) is significantly increasing worldwide.[...]
Karel Smetana   +2 more
openaire   +2 more sources

Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz   +12 more
wiley   +1 more source

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

open access: yesMolecular Cancer, 2021
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive ...
Gongmin Zhu   +4 more
doaj   +1 more source

Targeted cancer therapies [PDF]

open access: yesChinese Journal of Cancer, 2011
With unprecedented understanding of molecular events underlying human cancer in this genomic era, a large number of drugs specifically targeting hypothesized oncogenic drivers to which tumors are potentially addicted to have been developed and continue to be developed.
Yan, Li, Rosen, Neal, Arteaga, Carlos
openaire   +2 more sources

Social Functioning Within the First Years After Pediatric Brain Tumor Diagnosis and the Relationship With Family Psychosocial Risk

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben   +4 more
wiley   +1 more source

Characterization and Mechanistic Studies of a Novel Melanoma-Targeting Construct Containing IκBa for Specific Inhibition of Nuclear Factor-κB Activity

open access: yesNeoplasia: An International Journal for Oncology Research, 2010
The transcription factor nuclear factor-κB (NF-κB) is a central mediator of growth and homeostasis for both normal and neoplastic cells. IκBα is the natural intracellular inhibitor of NF-κB and can effectively complex with and thereby inhibit the ...
Hong Zhou   +9 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Targeted therapy in cancer [PDF]

open access: yesCancer Chemotherapy and Pharmacology, 2015
To describe the emergence of targeted therapies that have led to significant breakthroughs in cancer therapy and completed or ongoing clinical trials of novel agents for the treatment of patients with advanced cancer.The literature was systematically reviewed, based on clinical experience and the use of technologies that improved our understanding of ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy